Expanding Access, Enhancing Lives
Sarcomatrix’s commitment to commercialization ensures that our innovative therapies reach patients around the globe.
Target Markets
Sarcomatrix is committed to developing therapies for a wide range of muscle-wasting diseases. Our initial focus is on Duchenne and Becker Muscular Dystrophy, with plans to expand into additional forms of muscular dystrophy. We are also actively exploring programs targeting other muscle-wasting conditions, including chemotherapy-induced cachexia and age-related sarcopenia.
Commercial Strategy
While working toward our long-term vision of becoming a fully integrated pharmaceutical company, our strategy remains flexible. We are actively exploring potential exit opportunities, including co-development partnerships, out-licensing of larger indications such as Cachexia and Sarcopenia, or an outright acquisition.
Market Potential
Starting with the Duchenne Muscular Dystrophy market—projected to reach $13 billion by 2033—we are well-positioned to enter the U.S. market as early as 2028–2029, aligning with growing demand for effective, differentiated therapies.
Market Differentiation
As a first-in-class drug, our unique mechanism of action—targeting α7 integrin expression—offers the potential to be used as a standalone therapy or in combination with other treatments. Unlike approaches limited to single pathways or gene correction, our strategy supports all major muscle types, including skeletal, respiratory, and cardiac muscle—the latter being a leading cause of death in muscular dystrophy patients. This broad therapeutic reach positions Sarcomatrix to more effectively address the complex, systemic nature of the disease.
Brand Awareness & Marketing
In collaboration with patients, families, and advocacy groups, we aim to build market and brand awareness grounded in scientific credibility and patient-centered values. Our comprehensive campaign will position Sarcomatrix as a leader in muscle disease treatment, with a focus on our lead candidate, S-969. We will leverage a multi-channel approach—including digital marketing, social media, traditional advertising, and educational content—to engage stakeholders and drive visibility.
